AB-1002 is an investigational therapy administered through intracoronary infusion (delivered directly into the heart’s blood vessels). This medication is being studied for treating patients with heart failure, specifically those with non-ischemic cardiomyopathy (a type of heart muscle disease not caused by blocked arteries). The therapy aims to help patients who have severe symptoms of heart failure classified as New York Heart Association (NYHA) Class III, where patients experience marked limitations in physical activity.

Non-ischemic Cardiomyopathy – A heart muscle disease not caused by coronary artery disease or heart attacks. In this condition, the heart muscle becomes enlarged, thick, or rigid, making it harder for the heart to pump blood effectively. The condition develops gradually and can affect people of any age. It often leads to heart chambers becoming dilated and weakened over time. The disease can be inherited or develop due to various factors including infections, certain medications, or other medical conditions.

Congestive Heart Failure – A chronic condition where the heart muscle cannot pump blood as well as it should. The condition causes blood and fluid to back up in the body, leading to congestion in the lungs, legs, and other tissues. This results in symptoms such as shortness of breath, fatigue, and swelling in the legs and ankles. The condition typically progresses gradually, affecting the body’s ability to meet its oxygen needs. The heart tries to compensate by enlarging and developing more muscle mass.